Educational Sessions

Analysis Issues in Genome-Wide Association Studies

Quality control analysis in GWAS
Nancy J. Cox

Design and primary data analysis in GWAS
Laura J. Scott, Michigan State University, East Lansing, MI

GWAS in clinical trials
Kouros Owzar, Duke University Medical Center, Durham, NC

From Chemistry to the Clinic: Pathways for Drug Discovery and Development Part 1: Early Discovery and Lead Generation

Efficient and parallel lead discovery by high-throughput kinase profiling
Patrick Zarrinkar, Ambit Biosciences, San Diego, CA

The virtual kinome: The impact of computational methods on lead discovery and optimization
Jack A. Bikker, Wyeth Research, Pearl River, NY

Fragment-based drug discovery
Stephen W. Fesik, Abbott Laboratories, Abbott Park, IL

Mammary Tumor Modeling

Drug responses and therapy resistance in conditional mouse models of breast cancer
Jos Jonkers

Oncogene mediated signal transduction and transgenic mouse models of human breast cancer
William J. Muller, McGill University, Montréal, QC, Canada

Bottom-up approaches to understanding breast cancer metastasis and its treatment
Andy J. Minn, University of Chicago, Chicago, IL

Human-in-mouse model: Drug studies in human tissue transgenic breast tumors
Murray O. Robinson, AVEO Pharmaceuticals, Inc., Cambridge, MA

Mathematical Models of Tumor Growth and Drug Response

The grand challenge: Modeling growth and drug response at multiple scales
Vittorio Cristini

Mathematical models of tumor invasion and metastasis
Robert A. Gatenby, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

Mathematical modeling applications to translational oncology
Mary E. Edgerton, UT M. D. Anderson Cancer Center, Houston, TX

Approaches to modeling tumor vasculature and antiangiogenic therapy
Trachette L. Jackson, University of Michigan, Ann Arbor, MI

New Activation and Signal Amplification Strategies in Molecular Imaging

New activation mechanisms for optical molecular imaging of tumors
Hisataka Kobayashi, National Cancer Institute, Bethesda, MD

Complimentary molecular activation mechanisms in multimodel molecular imaging
Samuel Achilefu

In vivo imaging techniques for cancer and gene therapy
Daniel Meruelo, New York University School of Medicine, New York, NY

Cancer Nanotherapeutics

Nanoprobes for cancer diagnostics and imaging
Tuan Vo-Dinh, Duke University, Durham, NC

Nanophotonic PRET and ONCOS for cancer diagnostics and therapeutics
Luke P. Lee, University of California, Berkeley, CA

Delivery of nanotherapeutics in solid tumors: Barriers and strategies
Rakesh K. Jain, Massachusetts General Hospital, Boston, MA

Rational design of multistage cancer nanotherapeutics
Mauro Ferrari

From Chemistry to the Clinic: Pathways for Drug Discovery and Development Part 2: Emerging Molecular Targets

Introduction
Matthew V. Lorenzi

Discovery of small molecule sirtuin inhibitors through a p53 activation assay
Sonia Lain, University of Dundee, Dundee, United Kingdom

Selectively targeting protein ubiquitination with an inhibitor of Nedd8 activating enzyme
Teresa Soucy, Millennium Pharmaceuticals, Cambridge, MA

Targeting notch in cancer gamma secretase inhibitors
Christopher G. Winter, Merck Research Laboratories, Boston, MA

Functional Screens to Identify New Cancer Targets

Functional genomic approaches to identify cancer targets and co-dependencies
William C. Hahn

Cancer gene discovery through in vivo RNAi screens
Michael T. Hemann, MIT-Koch Institute for Integrative Cancer Research, Cambridge, MA

Genomic approaches to cancer drug discovery
Todd R. Golub, Broad Institute of MIT and Harvard, Cambridge, MA

High throughput screening and target validation
Markus Warmuth, Novartis Institutes for BioMedical Research, Inc., Cambridge, MA

Interethnic Differences in Response to Anticancer Agents

Introduction
Goh B. Cher

Race, ethnicity, and genetics
Shweta Choudhry, University of California, San Francisco, CA

Global pharmacogenomics
Sharon Marsh, Pharmacogenomics Centre, Montréal, QC, Canada

Pharmacogenetics of anticancer agents: East Asians as a susceptible population
Soo-Chin Lee, National University Health System, Singapore

Metastasis and Invasion: The Chemist’s Perspective

Drug targets in cancer metastasis
Georg F. Weber, University of Cincinnati Academic Health Center, Cincinnati, OH

Challenges in designing and evaluating drugs to impact metastasis: Targets, testing, and timing
Suzanne A. Eccles, Institute of Cancer Research, Sutton, United Kingdom

Genetically engineered tumor models as a platform to study metastasis
Murray O. Robinson, AVEO Pharmaceuticals, Inc., Cambridge, MA

Progress in Molecular Mechanisms of Pediatric Cancer

Integrated genomics and transcriptional mapping
Paul S. Meltzer, National Cancer Institute, Bethesda, MD

Therapeutic implications of ALK mutations in neuroblastoma
A. Thomas Look, Dana-Farber Cancer Institute, Boston, MA

Kinase alterations in pediatric cancer
Poul H. Sorensen, University of British Columbia, Vancouver, BC, Canada

Modeling of molecular aberrations in pediatric cancer
Katherine A. Janeway, Dana-Farber Cancer Institute, Boston, MA

The Immunologic Biomarkers of Cancer Diagnosis and Prognosis

Immune correlates of clinical outcomes in dendritic cell vaccination
Anna K. Palucka, Baylor Institute for Immunology Research, Dallas, TX

Immunologic signatures from the tumor microenvironment
Francesco M. Marincola, National Cancer Institute, Bethesda, MD

Early detection of cancer based on plasma autoantibody signatures
Samir M. Hanash, Fred Hutchinson Cancer Research Center, Seattle, WA

Immunologic biomarkers to predict vaccine efficacy
Mary L. Disis

The Transition from In situ to Invasive Breast Cancer

Clinical perspective
Monica Morrow, Memorial Sloan-Kettering Cancer Center, New York, NY

Role of genetic, genomic, and transcriptomic factors
Anne Vincent-Salomon, Institut Curie, Paris, France

Role of the microenvironment and stromal-epithelial interaction
Kornelia Polyak, Dana-Farber Cancer Institute, Boston, MA

Linear and non-linear models of progression from in situ to invasive breast cancer
Peter T. Simpson, University of Queensland, Brisbane, Australia

Aspects of the Tumor Microenvironment that Regulate Solid Tumor Development

Fibroblasts as regulators of the tumor microenvironment
Neil A. Bhowmick, Vanderbilt University, Nashville, TN

Tissue-specific regulation of cancer development by immune cells and their mediators
Barbara Fingleton, Vanderbilt University Medical Center, Nashville, TN

Tissue-specific programming of angiogenic vasculature and solid tumor development
Michele DePalma, San Raffaele Telethon Institute for Gene Therapy, Milano, Italy

Tissue-specific microRNAs and regulation of the tumor microenvironments
Bernhard Gentner, San Raffaele Telethon Institute for Gene Therapy, Milano, Italy

Cross-Talk Between Epigenetic Modifications and Non-coding RNAs in Human Cancer

Epigenetics and microRNAs: Patterns and machineries in human cancer
Manel Esteller

Noncoding RNA paradigms in medical practice
George A. Calin

Functional integration of microRNAs into oncogenic and tumor suppressor pathways
Joshua Mendell, Johns Hopkins University, Baltimore, MD

Cancerous miRNAs and regulatory binding proteins
Reuven Agami, The Netherlands Cancer Institute, Amsterdam, The Netherlands

EMT and Stem Cells

EMT in development and disease
Jean-Paul Thiery, A*STAR, Singapore

Links between EMT and stem cells
Sendurai A. Mani

Introduction to epithelial stem cells
Michael F. Clarke, Stanford University School of Medicine, Palo Alto, CA

Therapeutic resistance of breast cancer stem cells
Jeffrey M. Rosen, Baylor College of Medicine, Houston, TX

From Chemistry to the Clinic: Pathways for Drug Discovery and Development Part 3: Optimizing Drug Discovery–Insights on an Important Process

Biomarker driven optimization of novel KSP inhibitors
Kevin Koch, Array BioPharma, Inc., Boulder, CO

Discovery of ABT-263, an inhibitor of Bcl-2 family proteins for the treatment of cancer
Michael D. Wendt, Abbott Laboratories, Abbott Park, IL

The hedgehog pathway in cancer: The discovery of IPI-926
Julian Adams, Infinity Pharmaceuticals, Inc., Cambridge, MA

Pharmacogenomics in Assessing Cancer Therapy

Sequence variation – The next generation: Personal genomics
Deborah A. Nickerson, University of Washington, Seattle, WA

Approaches to identify pharmacogenomic markers
M. Eileen Dolan

Integrating pharmacogenomics into clinical trials
David A. Flockhart, Indiana University Cancer Center, Indianapolis, IN

Moving pharmacogenomics into mainstream medicine
Issam Zineh, U. S. Food and Drug Administration, Baltimore, MD

Precision Medicine – Optimization of Diagnostics: The Innovator’s Prescription

Disruptive innovations in medicine
John Kenagy, Kenagy and Associates, Inc., Belmont, MA

Bringing precision medicine to patients: High hopes and high hurdles
Lisa L. von Moltke, Millennium Pharmaceuticals, Inc., Cambridge, MA

Coupled diagnostics and biologically targeted therapeutics in colon cancer
Edward Chu, Yale Cancer Center, New Haven, CT

HER2 testing in breast cancer: Lessons learned
Nita J. Maihle

What Causes Cancer? Epidemiology Beyond Genes

Physical activity, energy balance, and cancer
Tim Byers, University of Colorado Health Sciences Center, Aurora, CO

Viruses, immunity, and cancer
Eric A. Engels, National Cancer Institute, Rockville, MD

Environment and occupational cancer research in the age of genomics
Nathaniel Rothman, National Cancer Institute, Bethesda, MD

Approaches for In vivo Real-Time Imaging of Distinct Cellular Populations in Tumors

Imaging inflammatory cell dynamics in different tumor microenvironments
Mikala Egeblad

Cellular interactions regulating the antitumor T cell response
Thorsten Mempel, Massachusetts General Hospital, Charlestown, MA

Cancer cell invasion in complex environments
Erik Sahai, Cancer Research UK London Research Institute, London, United Kingdom

Watching tumor behavior in transparent adult zebrafish
Richard M. White, Dana-Farber Cancer Institute, Boston, MA

Biology and Genetics of Metastasis

Metastasis and metastasis suppressors
Danny R. Welch, University of Alabama, Birmingham, AL

Intrinsic and exogenous factors in metastatic progression
Kent W. Hunter

The molecular underpinnings of tumor cell plasticity
Mary J. C. Hendrix, Children’s Memorial Research Center, Chicago, IL

Identifying breast cancer metastasis pathways by multi-dimensional genomic analysis
John A. Foekens, Erasmus Medical Center, Rotterdam, The Netherlands

Cancer as an Ecological and Evolutionary Process

Cancer as an ecological and evolutionary process
Carlo C. Maley

Evolutionary dynamics of cancer
Franziska Michor, Memorial Sloan-Kettering Cancer Center, New York, NY

Evolutionary considerations in cancer therapy
Robert A. Gatenby, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

Evolutionary strategies for avoiding acquired drug resistance in cancer
John Pepper, University of Arizona, Tucson, AZ

Epigenetic Therapies to Overcome Resistance

In vivo epigenetic modulation after DNA hypomethylation therapy
Jean-Pierre Issa, UT M. D. Anderson Cancer Center, Houston, TX

DNA methylation inhibitors for chemotherapy resensitization of solid tumors
Kenneth P. Nephew

Combined therapy with agents targeted against deregulated epigenetic mechanisms in cancer
Kapil N. Bhalla, Medical College of Georgia Cancer Center, Augusta, GA

Epigenetic alterations as determinants of cancer response
James G. Herman, Johns Hopkins University School of Medicine, Baltimore, MD

From Chemistry to the Clinic: Pathways for Drug Discovery and Development Part 4: Chemical Development – Translating a Potent Agent into a Registered Product

Chemical development: Translating a potent agent into a registered product
Stephen A. Munk

Conception to the clinic: Cancer drug discovery and development at Southern Research Institute
John A. Secrist, III, Southern Research Institute, Birmingham, AL

Challenges in the process and pharmaceutical development of an oncology product
Sue Wollowitz, Medivation, Inc., San Francisco, CA

Chemical, analytical, and formulation development of an important cancer drug: A case study
Poh K. Hui, Millennium Pharmaceuticals, Inc., Cambridge, MA

Targeting Tumor Vasculature for Imaging and Therapy

Imaging tumor vasculature during anti-angiogenic therapy: Bench to bedside to biomarkers
Rakesh K. Jain

Combinatorial vascular targeting by in vivo phage display
Renata Pasqualini, UT M. D. Anderson Cancer Center, Houston, TX

New molecular insights into vascular remodeling and angiogenesis
David A. Cheresh, Moores UCSD Cancer Center, La Jolla, CA

New vascular targets and principles on the horizon for anticancer therapy
Peter Carmeliet, University of Leuven, Leuven, Belgium

Tumor Microenvironment: Pro- and Antitumor Immunity

Tumor-specific Th1 lymphocytes: Modulation of the tumor microenvironment to enhance cross-priming
Mary L. Disis, University of Washington, Seattle, WA

NKT cells and cancer: Two subsets form a new immunoregulatory axis
Masaki Terabe, National Cancer Institute, Bethesda, MD

Macrophages orchestrate the tumor microenvironment
Mario P. Colombo, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy

Regulation of dendritic and myeloid derived suppressor cell function by the tumor microenvironment
Dmitry I. Gabrilovich, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL